“we hope to update later data later this year. Start the phase two study this year, and then next year, the phase three study for the combination.”

In context

“ltra-high efficacy tier with agents like Lilly's g g g, or is the value add potentially more in GLP-1 non-responders? Just sort of curious because it seems like what you have with the monotherapy approach can make you competitive with ZEPBOUND and Meritide. So just sort of curious how you think about the combo and where that fits. Albert Bourla: Why don't I ask Chris to give a little bit of science behind this combination, and then we'll ask Aamir and Alexandre to comment on how that can be marketed. Chris Boshoff: Yeah. We will have optionality because we are developing in place through both the single agent 3944 as well as the combination 3944 plus 3945. Everything we've seen thus far suggests to us, to your point, that we should get increased efficacy for the combination and that's why we hope to update later data later this year. Start the phase two study this year, and then next year, the phase three study for the combination. Albert Bourla: And then, Aamir, how do you think this playing as a portfolio? Aamir Malik: Yeah. Jason, so I think the quick answer would be, look. I think we're in the very early innings of a large market where there is still significant unmet need. Right? There's more convenient dosing that's needed, higher weight loss for certain BMI patients, GI tolerabilities need to improve, maintenance strategies, friction in the patient journey. So our belief is that there's not gonna be one single asset that serves all those patients. People are going to have different starting points, goals, preferences on their dosing and route of administration, comorbidities, their willingness to pay. And what you need to win in a market like that is, one, you need a great portfolio of products that can serve”